Biogen Idec achieved positive results from DEFINE, a Phase III trial evaluating the investigational oral compound BG-12 (dimethyl fumarate) as a monotherapy in people with relapsing-remitting multiple sclerosis (RRMS). Results showed that 240 mg of BG-12, administered either twice or three times a day, met the primary study endpoint, demonstrating a statistically significant reduction in patients with RRMS who relapsed at two years compared with placebo. Both doses of BG-12 also met all of the s...